Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Cancer medicines: a private vice for public benefit?

Richard Sullivan

Published 30 Jan 2024

https://doi.org/10.3332/ecancer.2024.ed131

PDF

Upheaval in cancer care during the COVID-19 outbreak

Omolola Salako, Kehinde Okunade, Matthew Allsop, Muhammedu Habeebu, Mariam Toye, Glory Oluyede, Gabriel Fagbenro, Babatunde Salako

Published 1 Apr 2020

https://doi.org/10.3332/ecancer.2020.ed97

PDF

Cost-effectiveness and affordability of anticancer treatment in Brazil

Pedro Nazareth Aguiar

Published 20 Jan 2020

https://doi.org/10.3332/ecancer.2020.ed96

PDF

ecancer—towards effective global cancer control through innovation, collaboration and dissemination

Eduardo Cazap

Published 1 Apr 2019

https://doi.org/10.3332/ecancer.2019.ed90

PDF

Welcome to Eduardo Cazap, Editor-in-Chief, ecancer

Gordon McVie

Published 1 Apr 2019

https://doi.org/10.3332/ecancer.2019.ed89

PDF

Drug interactions and oncological outcomes: a hidden adversary

Rachel P Riechelmann, Monika K Krzyzanowska

Published 28 Mar 2019

https://doi.org/10.3332/ecancer.2019.ed88

PDF

Propranolol and breast cancer—a work in progress

Pan Pantziarka, Brad A Bryan, Sergio Crispino, Erin B Dickerson

Published 18 Jun 2018

https://doi.org/10.3332/ecancer.2018.ed82

PDF

Does the oncology community have a rejection bias when it comes to repurposed drugs?

Bishal Gyawali, Pan Pantziarka, Sergio Crispino, Gauthier Bouche

Published 16 Jan 2018

https://doi.org/10.3332/ecancer.2018.ed76

PDF

Personalising your health: an EU imperative

Denis Horgan

Published 11 Jul 2017

https://doi.org/10.3332/ecancer.2017.ed68

PDF

The potential consequences for cancer care and cancer research of Brexit

Peter Selby, Mark Lawler, Richard Baird, Ian Banks, Patrick Johnston, Paul Nurse

Published 24 Feb 2017

https://doi.org/10.3332/ecancer.2017.ed63

PDF

More from ecancer